Announcements Trials

Browse Landscape

Phase

Status

Not yet recruiting 2 Recruiting 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 660 Carcinoma, Non-Small-Cell Lung 454 Prostatic Neoplasms 384 Neoplasms 376 Lung Neoplasms 261 Multiple Myeloma 246 Colorectal Neoplasms 231 Neoplasm Metastasis 214 Melanoma 202 Leukemia, Myeloid, Acute 165 Ovarian Neoplasms 163 Pancreatic Neoplasms 155 Carcinoma, Renal Cell 141 Squamous Cell Carcinoma of Head and Neck 137 Lymphoma 134 Brain Neoplasms 132 Leukemia, Lymphocytic, Chronic, B-Cell 126 Glioblastoma 126 Recurrence 123 Lymphoma, Non-Hodgkin 123 Carcinoma, Hepatocellular 117 Head and Neck Neoplasms 114 Urinary Bladder Neoplasms 111 Triple Negative Breast Neoplasms 107 Stomach Neoplasms 106 Precursor Cell Lymphoblastic Leukemia-Lymphoma 104 Uterine Cervical Neoplasms 100 Hematologic Neoplasms 99 Lymphoma, Follicular 95 Sarcoma 93

Interventions

talazoparib 1 enzalutamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Active not recruiting × mCRPC × 1 year × Clear all

NCT03395197 2026-04-22

TALAPRO-2

Pfizer

Phase 3 Active not recruiting

1,054 enrolled 21 charts 1 FDA

mCRPC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡